Merck Receives 2015 European Human Growth Hormone Leadership Award
Each year, this award is presented to the company that has leveraged competitive intelligence to successfully execute a strategy that results in stronger market share, competitive brand positioning and customer satisfaction. This years? decision was taken based on Frost & Sullivan's recent analysis of the human growth hormone (hGH) market.
While with Saizen(r) endogenous growth hormone deficiency in children and adults is treated, Merck's ambition is to raise patient compliance to benefit healthcare systems, doctors and most importantly patients.
Simon Sturge, Chief Operating Officer of Merck?s biopharma business, sees the award as another proof point of fulfilling Merck's aspiration of patient centricity. "Helping patients to live a better life is what we strive for at Merck. Innovative products like the easypod system are examples of our constant entrepreneurial spirit that drives us to improve the medical care for the benefit of our patients. Being awarded for Competitive Strategy Innovation and Leadership shows us that our ambition is truly reaching those we work for."
As the majority of patients with hGH deficiency are children, adherence to drug treatment is a critical concern. Merck has tackled this issue head-on with a combination of its recombinant growth hormone (r-hGH) drug Saizen and the related easypod device system.
"Merck pioneered the first and only electronic, automated human growth hormone drug delivery device, the easypod," said Frost & Sullivan Director Tonya Fowler. "The easypod is easy to use via its single-touch, soft-push technology, but the electronic recording of each injection and dose is the most important feature, as this recording helps doctors and patients more effectively track the drug treatment."
The easypod device system consists of three integrated elements: easypod injection device, easypod connect data transmitter, and Web- or Cloud-based easypod connect software. These combine to offer real-time electronic recording of the dose administration and accessibility of this information for the healthcare professional. The injection and dose history is stored and managed through easily readable reports that healthcare professionals can use to monitor patient's adherence. More importantly, this data helps promote an informed conversation between physicians and their patients to address any potential questions. This opens up dialogue opportunities related to adherence and treatment dosages, which helps in the overall care delivery to the patient.
Additionally, Frost & Sullivan considered that for Europe Merck offers telephone patient support programs related to its injection devices and the easypod connect system where deployed. The service is available 24/7, employs highly trained patient support representatives, and aids with device use, treatment information, reimbursement support, device refill supplies, and referrals to trainers for personal device use.
Easypod's real-time electronic recording can demonstrate to patients, physicians and even payers that the full dose has been correctly administered with every injection. This reduces instances of incomplete dosing and drug wastage, thereby lowering the total cost burden, and can help to improve overall patient outcomes. Additionally, it may lead to management benefits for patients, physicians and payers.
Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry